| Literature DB >> 36059618 |
Xiaodan Huang1, Xiangyu Wang1, Xinxin Lan1, Jinhuan Deng1, Yi Lei1, Fan Lin1.
Abstract
Bladder cancer is a common malignant tumor in the urinary system. Depending on whether bladder cancer invades muscle tissue, it is classified into non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). It is crucial to accurately diagnose the muscle invasion of bladder cancer for its clinical management. Although imaging modalities such as CT and multiparametric MRI play an important role in this regard, radiomics has shown great potential with the development and innovation of precision medicine. It features outstanding advantages such as non-invasive and high efficiency, and takes on important significance in tumor assessment and laor liberation. In this article, we provide an overview of radiomics in the prediction of muscle-invasive bladder cancer and reflect on its future trends and challenges.Entities:
Keywords: CT; MRI; bladder cancer; machine learning; muscle-invasive; radiomics
Year: 2022 PMID: 36059618 PMCID: PMC9428259 DOI: 10.3389/fonc.2022.990176
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 5.738
Figure 1PRISMA flowchart of included studies.
Studies included in the systematic review.
| Study characteristics | Patient characteristics | Imaging characteristics | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Author | Year | Study design | Number of cases | Number of selected lesions | Surgical technique | Pathological stage NMIBC: MIBC | Imaging modality | Scanner | |
| 1 | Xu | 2017 | Single-center retrospective | 78 | 118 | NA | 34:84 | T2WI | 3.0T GE |
| 2 | Garapati | 2017 | Single-center retrospective | 76 | 84 | Cystectomy | 43:41 | CTU | NA |
| 3 | Tong | 2018 | Single-center retrospective | 65 | 65 | Cystectomy | 31:34 | T2WI | 1.5-3.0T |
| 4 | Xu | 2019 | Single-center retrospective | 54 | 54 | NA | 24:30 | T2WI、DWI、ADC | 3.0T GE |
| 5 | Zheng | 2019 | Single-center retrospective | 199 | 199 | RC or TURBT | 130:69 | T2WI | 3.0T MR scanner (Intera Achieva, Philips Medical Systems) |
| 6 | Xu | 2020 | Single-center retrospective | 218 | 218 | Both TURBT and RC | 131:87 | DWI | 3.0T MR scanner (Ingenia;Philips Healthcare) |
| 7 | Wang | 2020 | Mult-center retrospective | 106 | 106 | RC or partial cystectomy or TURBT | 64:42 | T2WI、DWI、ADC | 3.0T MR system (MAGNETOM Trio, Siemens Healthineers) |
| 8 | Hammouda | 2021 | Single-center retrospective | 42 | NA | T2WI、DWI、ADC | 3.0T Ingenia Philips MRI scanners | ||
| 9 | Zhang | 2021 | Mult-center retrospective | 441 | 441 | RC or TURBT | 183(development):110(tuning ) | Enhanced CT | NA |
| 10 | Zheng | 2021 | Single-center retrospective | 185 | 185 | NA | 129:56 | T2WI、DCE | 3.0T MRI scanner(Magnetom Verio: Siemens, Erlangen, Germany) |
| 11 | Zhou | 2021 | Single-center retrospective | 100 | 100 | NA | 70:30 | Enhanced CT | Siemens 64-row spiral CT |
| 12 | Cui | 2022 | Single-center retrospective | 327 | 188 | RC or partial cystectomy or TURBT | 120:68 | CECT | GE Dis covery CT750HD, GE LightSpeed VCT, Philips ICT 256, and Siemens Somatom Definition Flash. |
ADC, apparent diffusion coeffificient; CECT, contrast-enhanced computed tomography; CT, computed tomography; CTU, CT Urography; DCE, dynamic contrast enhanced; DWI, diffusion-weighted imaging; MIBC, muscle-invasive bladder cancer; MR, magnetic resonance; MRI, magnetic resonance imaging; NA, not available; NMIBC, non–muscle-invasive bladder cancer; RC, radical cystectomy; TURBT, transurethral resection of bladder tumor; T2WI, T2-weighted imaging.
Radiomic characteristics of studies included in the systematic review.
| Author | Segmentation method | Radiomic feature categories | Machine-learning method for feature selection | Number of selected features | Model | AUC of radiomic model with the best performance | clinical factor | AUC of radiomic-clinical model | ||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
| |||||||
| Xu | Semi-automatic segmentation(3D) | Signal intensity histogram-based features and 3D ND-Haralick texture features based intensity and its high-order derivative maps | SVM-RFE","SMOTE | 13 | SVM-RFE | 0.861 | NA | NA | NA | NA |
| Garapati | Automatic segmentation(3D) | First-order statistics, shape, contrast, GLRLM, | Stepwise feature selection | 3 subsets of radiomic features | LDA, NN, SVM, RF | 0.97 | NA | NA | NA | NA |
| Tong | Manual segmentation(3D) | LBP、GLCM | An optimal biomarker approach | 9 | SVM | Patient level:0.806,radial sector level:0.813 | NA | NA | NA | NA |
| Xu | Manual segmentation(2D) | Histogram, CM , RLM, | SVM-RFE","SMOTE, | 19 | SVM-RFE | 0.9857 | NA | NA | NA | NA |
| Zheng | Semi-automatic segmentation(3D) | first-order statistics,shape-based,GLCM,GLRLM,GLSZM,NGTDM,and GLDM | LASSO LR | 23 | LASSO | 0.913;Optimism-corrected:0.912 | 0.874 | Tumor size | 0.922;optimism-corrected AUC of 0.921 | 0.876 |
| Xu | Manual segmentation and automatic segmentation(3D) | First-order intensity features,high-order texture features,and shape ,GLCM,GLRLM,GLSZM and NGTDM | Boruta | 21 | RF, AR | .0.907 | 0.904 | RandomForest model and TURBT | NA | NA |
| Wang | Manual segmentation and automatic segmentation(2D) | Histogram , CM, RLM, NGTDM and GLSZM | SVM-RFE | 36 | LR, LASSO | 0.88 | external validation cohort 0.813 | Radscore and tumor stalk | 0.924 | 0.877 |
| Hammouda | Automatic segmentation(3D) | Histogram ,GLCM,GLRLM,and morphological features | NA | NA | NN(best)","RF,SVM | 0.9864 | NA | NA | NA | |
| Zhang | Semi-automatic segmentation(3D) | NA | NA | NA | FGP-Net | development cohort:0.936, tuning cohort:0.891 | internal validation cohort: 0.861,external validation cohort: 0.791 | NA | NA | NA |
| Zheng | manual segmentation (3D) | shape and size-based features, image intensity, textural features and wavelet features | mRMR | 40 | Lasso(best)、SVM、RF | 0.934 | 0.906 | VI-RADS | 0.97 | 0.943 |
| Zhou | semi-automatic segmentation(3D) | GLDM,Shape2D,GLCM,Shape3D,First-order,GLRLM,GLSZM,and NGTDM | SVM-RFE | 6 | LR, Decision Tree, SVM(best), and Adaboost algorithm | 0.898 | 0.702 | Rad-score, albuminuria and metabolic syndrome | 0.8457 | |
AR, all-relevant model; AUC, area under the curve; CM, Co-occurrence matrices; 3D, three dimensional; 2D, two dimensional; FGP-Net, Filter-guided Pyramid Network; GLCM, grey-level co-occurrence matrix; GLDM, gray level dependence matrix; GLRLM, gray-level run length matrix; GLSZM, gray-level size zone matrix; LASSO, least absolute shrinkage and selection operator; LBP, local binary pattern; LDA, linear discriminant analysis; LR, logistic regression; mRMR, min-redundancy; NA, not available; ND, nondirectional Haralic textural features; NN, neural network; NGTDM, neighborhood gray-tone difference matrix; RF, random forest model; RFE, recursive feature elimination; RLM, run length matrix; SMOTE, synthetic minority oversampling technique; SVM, support vector machine classififier; TURBT, transurethral resection of bladder tumor.